NRX Pharmaceuticals, Inc.

NRX Pharmaceuticals, Inc. (Nasdaq: NRXP) is a clinical-stage biopharmaceutical company focused on treatments for central nervous system disorders and acute respiratory conditions. The company filed a Form 10-Q with the SEC on August 14, 2019, under accession number 0001654954-19-009612, representing an early quarterly disclosure in its public reporting history. NRX Pharmaceuticals reached the public markets through its merger with Big Rock Partners Acquisition Corp, a blank-check company sponsored by Big Rock Partners that completed its IPO in 2020; the de-SPAC transaction closed in May 2021. The company operates in the biopharmaceutical sector. Sign up on SpacDesk for complete filing history, sponsor intelligence, and deal analytics across the SPAC universe.